Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets

Author(s): Shilpika Pandey, Sarthak Gaur, Neha Topno, Sidharth Chopra, Arunava Dasgupta.

Journal Name: Current Respiratory Medicine Reviews

Volume 10 , Issue 2 , 2014

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

There are many chemotherapeutic interventions available for tuberculosis (TB) and are in use for more than five decades, but still there is an urgent need for novel drugs against new targets due to emergence of resistant strains. Moreover, the ability of Mycobacterium tuberculosis (Mtb) to survive within granulomas in a non-replicating latent stage prolongs the course of drug dose and hence increases the severity of the disease. The significant rerouting of metabolism is one of the key processes that help mycobacteria adapt to the hostile environment of host granuloma. In this review, we are focusing on some of the cofactor biosynthetic pathways of Mycobacterium tuberculosis and their utilization as drug targets.

Keywords: FAD, Mtb, NAD, Pantothenate, iron, vitamin.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 2
Year: 2014
Page: [97 - 108]
Pages: 12
DOI: 10.2174/1573398X10666140822004506
Price: $58

Article Metrics

PDF: 13